,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['tnbc', 'mbc', 'bcsm', 'breast', 'destiny-breast04']
destiny-breast04: t-dxd vs treatment of physician's choice in her2-low breast cancer (her2 ihc 1+ or 2+/fish-). pfs/os benefit in hr+, tnbc, and across all subgroups. impacts ~50% of all patients with mbc. shanu modi of #bcsm #asco22 
Medical oncologist @Intermountain, Director of Breast Oncology. Clinical research, quality improvement, cardio-oncology, provider wellness. All tweets my own.